Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Leukemia

Topics

Medicine

Cancer Oncology

Internal Medicine

Hematology

Gastroenterology

Show all topics

DOI

10.1038/s41375-019-0602-x

License

CC-BY

Other Formats

PDF